Although there has been abundant research on chronic low-grade inflammation as a potential mechanism underlying the link between mood disorders and cardiovascular risk, less is known about the role of inflammatory factors and anxiety disorders. The aim of this paper is to evaluate the bi-directional associations between inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-, and high sensitivity C-reactive protein (hsCRP) with anxiety disorders and its subgroups.
INTRODUCTION
There is consistent evidence for a potent association between anxiety disorders and medical conditions, particularly cardiovascular risk factors (CVRFs) and diseases (CVDs) (Furtado, & Katzman, 2015; Glaus et al., 2013; Tully, Cosh, & Baune, 2013; Van der Kooy et al., 2007) .
Medical comorbidity is associated with substantially greater disability than anxiety disorders alone (Furtado, & Katzman, 2015) . Recent research has examined the role of chronic low-grade inflammation as a potential mechanism underlying the association between anxiety disorders and CVRFs/CVD (Furtado, & Katzman, 2015; Salim, Chugh, & Asghar, 2012) . Insight into the role of inflammation in anxiety disorders could inform novel treatments and reduce the risk of anxiety disorders through the prevention of chronic inflammation. Compared to depression, studies on the role of the immune system in anxiety disorders are scarce, and it is still unclear to which degree chronic inflammation is implicated in their etiology and consequences (Furtado, & Katzman, 2015; Salim et al., 2012; Turna, Grosman Kaplan, Anglin, & Van Ameringen, 2016) . Psychological stress related to anxiety disorders has been shown to dysregulate the hypothalamic-pituitary-adrenal (HPA) axis with an activation of the innate inflammatory response, evidenced by increases in interleukin (IL)-1 , IL-6, and tumor necrosis factor (TNF)-, as well as the C-reactive protein (CRP) (Furtado, & Katzman, 2015) .
Moreover, increased oxidative stress could lead to chronic activation of proinflammatory markers which could alter anxiety disorders, such as generalized anxiety disorder (GAD), social phobia, and panic disorder (Salim et al., 2012) .
Existing literature on the associations between aggregate anxiety disorders and specific subtypes thereof with increased inflammation is limited and comorbidity with other mental disorders has not always been taken into consideration (Gill, Saligan, Woods, & Page, 2009; Khandaker, Zammit, Lewis, & Jones, 2016; Liukkonen et al., 2011; Pitsavos et al., 2006; Turna et al., 2016; Vogelzangs, Beekman, de Jonge, & Penninx, 2013) . With respect to specific subtypes of anxiety, the most consistent evidence has been found for increased levels of inflammatory markers with posttraumatic stress disorder (PTSD) (Gill et al., 2009; Spitzer et al., 2010; von Kanel et al., 2007) . Moreover, a recent cross-sectional study of adolescents found an association between GAD and increased CRP levels (Khandaker et al., 2016) . Evidence for an association between inflammatory markers and obsessive-compulsive disorder (OCD) has also been found, even though results of a series of studies are inconsistent (Turna et al., 2016) . Although previous research consistently shows increased levels of inflammation in anxiety disorders, longitudinal studies that can inform the ordinal patterns of inflammation with respect to the onset and recurrence of anxiety disorder subtypes are necessary to inform potential mechanisms for these associations. The only prospective study of inflammatory factors and anxiety in a community sample of youth showed a bidirectional association between GAD and CRP that was attenuated after controlling for the mediating effect of body mass index (BMI) and medication use (Copeland, Shanahan, Worthman, Angold, & Costello, 2012) . Our previous analyses of inflammation and agoraphobia showed that a history of agoraphobia was associated with subsequent increase in CRP and TNF-levels (Wagner et al., 2015) . Accordingly, the aims of the present study were: (1) to evaluate the specificity of 5-year prospective associations between aggregate anxiety disorders and specific subtypes, (i.e., GAD, social phobia, panic disorder, agoraphobia, OCD, and PTSD), and changes in circulating levels of specific inflammatory markers (IL-6, TNF-, hsCRP); (2) to assess the directional associations between inflammatory markers and anxiety disorders and subtypes; (3) to examine whether the markers comprise state versus trait indices by comparing remitted versus current disorders, as well as incident cases; and (4) to examine the role of health behaviors, CVRFs, and treatment factors that may influence these associations.
MATERIALS AND METHODS

Study sample
The data of the present investigation were drawn from CoLaus|PsyCoLaus (Firmann et al., 2008; Preisig et al., 2009 ), a cohort study designed to prospectively assess the associations of mental disorders with CVD and CVRFs in the community. The sample was randomly selected from the civil register of the city of Lausanne (85.8% participation). Among these, 61 participants were excluded due to missing information on inflammatory markers both at baseline and follow-up, 14 subjects were excluded due to missing information on mental disorders and three subjects were excluded due to missing information on CVRFs. The final sample used to examine associations between anxiety disorders at baseline and inflammation at follow-up consisted of 3,113 participants in total (53.7% women; mean age: 51.0, S.D. 8.8 years): 2,791 participants were analyzed for cytokine levels and 2,891 for hsCRP levels. The mean follow-up duration was 5.5 years (S.D. 0.6 years). The number of participants with data from the psychiatric evaluation at follow-up was 2,833. Among these, 258 participants were excluded due to missing information on inflammatory markers and two participants were excluded due to missing information on CVRFs. The resulting number of participants used to determine the association between inflammation at baseline and anxiety disorders at follow-up was 2,573. The Institutional Ethics' Committee of the University of Lausanne approved the CoLaus and the PsyCoLaus study. All participants provided written informed consent for the study protocol.
Measurements
Anxiety disorders and comorbid disorders
Mental disorders at baseline and follow-up were assessed using the French version (Leboyer et al., 1995) of the semistructured Diagnostic Interview for Genetic Studies (DIGS), which was developed and validated by the National Institute of Mental Health (Nurnberger et al., 1994) . The French version of this instrument (Leboyer et al., 1995) revealed adequate interrater reliability in terms of kappa and Yule's coefficients for major mood and psychotic disorders (Preisig, Fenton, Matthey, Berney, & Ferrero, 1999) as well as substance use disorders (Berney, Preisig, Matthey, Ferrero, & Fenton, 2002) , whereas the 6-week test-retest reliability was slightly lower (Berney et al., 2002; Preisig et al., 1999) . The DIGS was completed with sections on GAD, PTSD and phobia disorders using questions from the Schedule for
Affective Disorders and Schizophrenia -Lifetime and Anxiety disorder F I G U R E 1 Flow chart of the study for the association between anxiety disorders at baseline and inflammatory markers at follow-up and for the association between inflammatory markers at baseline and anxiety disorders at follow-up. hsCRP, high-sensitivity C-reactive protein. Baseline assessment; follow-up assessment for the association between anxiety disorders at baseline and inflammatory markers at follow-up; follow-up sample for the association between inflammatory markers at baseline and anxiety disorders at follow-up version (SADS-LA (Endicott, & Spitzer, 1978) ), which also revealed sat- The Yule coefficient for the overall category of anxiety disorders was 0.49 (Leboyer et al., 1991) . In our own reliability study, we found excellent or perfect interrater reliability for all specific anxiety disorders except for agoraphobia (Yule's Y = 0.96), whereas the 6-week test-retest reliability estimates were 0.58 for panic disorder, 0.55 for agoraphobia, 0.44 for social phobia, and 0.77 for specific phobia (Rougemont-Buecking et al., 2008) . Interviewers were required to be masters-level psychologists and were trained over a 2-month period.
In order to provide ongoing supervision throughout the study, each interview and diagnostic assignment was reviewed by an experienced senior psychologist. Diagnoses were assigned according to the Diagnostic and statistical manual of mental disorders (4th ed., text rev.).
Anxiety disorders included GAD, social phobia, panic disorder, agoraphobia, OCD, and PTSD. For this study, anxiety disorders were defined as current if they were present at the time of the physical evaluation.
Inflammatory markers
HsCRP was assessed during baseline and follow-up physical evaluations using immunoassay and latex HS (IMMULITE 1000-High, Diagnostic Products Corporation, LA, CA, USA), with maximum intraand interbatch coefficients of variation of 1.3% and 4.6%, respectively (Firmann et al., 2008 ). Subjects with a hsCRP level higher than 10 mg/L were excluded as an elevation of this magnitude is likely to be attributable to acute infection (Pearson et al., 2003) .
For the baseline and follow-up cytokine measurements, serum was preferred to plasma, as it has been shown that different anticoagulants may differentially affect absolute cytokine levels (Skeppholm, Wallen, Blomback, & Kallner, 2008) . Serum samples were stored at -80 • C before assessment and sent on dry ice to the laboratory. Cytokine levels were measured using a multiplexed particlebased flow cytometric cytokine assay (Marques-Vidal et al., 2011) .
Lower detection limits (LOD) for IL-6 and TNF-were 0.2 pg/mL.
Good agreement between signal and cytokine was found within the assay range (R 2 ≥ 0.99).
Covariates
Data were collected on age, race (Caucasian vs. non-Caucasian), marital status (living alone vs. living with someone) and healthrelated behaviors at baseline including smoking (never, former, current) and physical inactivity (no or low vs. at least 20 min twice a week). Information on socioeconomic status (SES) and on psychotropic drug treatment was derived from the DIGS. The level of SES was assessed using the Hollingshead scale (Hollingshead, 1975 
Statistical analysis
Statistical analyses were conducted using the Statistical Analysis System (SAS Institute Inc., Cary, NC, USA), version 9.3 for Windows.
Age was standardized. Descriptive data for demographic characteristics, comorbid disorders, medication, health-related behaviors, physical risk factors for CVD, and inflammatory marker levels were derived by lifetime anxiety disorders, and Chi-square, and Kruskal-Wallis tests were used to determine the difference between anxiety disorders. The tests were two-tailed and P-values were not adjusted for multiple testing because the hypothesized associations between anxiety disorders and inflammatory markers were specified a priori.
Associations between current and remitted anxiety disorders at baseline and levels of inflammatory markers at follow-up with adjustment for the respective levels at baseline were determined using multiple linear regression models. Because we adjusted 5-year inflammatory markers for the corresponding inflammatory marker level at baseline, the follow-up variables represent change scores Associations between inflammatory markers at baseline and a history of anxiety disorders during the follow-up period were assessed using logistic regression models. Two models were computed. Model 1 included all inflammatory markers simultaneously, adjusting for the corresponding history of anxiety disorder at baseline. Model 2 was further adjusted for the length of follow-up, sociodemographic characteristics, medications, health-related behaviors, and physical risk factors for CVD.
RESULTS
Sample characteristics
The description of the cohort of 3,113 participants used for the assessment of the prospective associations between anxiety disorders at baseline and the concentrations of inflammatory markers at follow-up is presented in and no anxiety disorders (1.10 [0.60-2.10]) at follow-up were statistically different among the three diagnostic groups (P = 0.023).
Since no significant sex interactions were found, models were run for males and females together.
Associations between anxiety disorders at baseline and inflammatory markers at follow-up
Associations between current and remitted anxiety disorders at baseline and levels of inflammatory markers at follow-up with adjustment for the respective level at baseline are presented in Tables 2 and 3 .
When models were only adjusted for the corresponding inflammatory marker at baseline (Table 2) , current anxiety disorders, as well as current agoraphobia were associated with a steeper increase of hsCRP levels over the follow-up period. In contrast, current PTSD was associated with a lower increase of IL-6 levels over the follow-up period.
No significant associations were found for remitted anxiety disorders with inflammatory markers. When the model was further adjusted for potential confounders, including depression, current anxiety disorders were still significantly associated with hsCRP levels (Table 3) 
Inflammatory markers at follow-up, Median (IQR)
Interleukin a steeper increase of TNF-levels over the follow-up period in the fully adjusted model. Finally, the association between current PTSD and a lower increase of IL-6 levels over the follow-up period remained significant.
TA B L E 2 Associations between current and remitted anxiety disorders at baseline and inflammatory markers at follow-up
Associations between inflammatory markers at baseline and anxiety disorders at follow-up
Levels of the 3 inflammatory markers at baseline were not associated with any lifetime anxiety disorder at follow-up in either model (Table 4) .
We also tested the associations between inflammatory markers at baseline and incident cases of anxiety disorders excluding subjects that already had a lifetime history of these disorders at baseline. However, no significant associations were found (results not shown).
DISCUSSION
Based on a large adult cohort with comprehensive physical and psychiatric evaluations at baseline and follow-up, we found significant associations between current anxiety disorders in general, and current agoraphobia specifically, at baseline with a steeper increase of hsCRP levels over a more than 5-year follow-up period. Moreover, current PTSD at baseline was associated with a lower increase of IL-6 levels over the follow-up period. These associations remained significant after adjustment for a comprehensive array of potential confounders, including major depressive disorder. No evidence was found for associations between the other anxiety disorder subtypes with any proinflammatory markers.
Consistent with previous literature, anxiety disorders were associated with a steeper increase of hsCRP levels over the follow-up period after adjustment for multiple covariates (Liukkonen et al., 2006; Pitsavos et al., 2006; Vogelzangs et al., 2013) . Our further evaluation of specific subtypes of anxiety disorders that may explain this association revealed that the findings regarding hsCRP were specifically attributable to agoraphobia, confirming our previous analyses of lifetime anxiety disorders with inflammatory markers (Wagner et al., 2015) . Similar to previous findings (Khandaker et al., 2016; Pitsavos et al., 2006; Vogelzangs et al., 2013) , these results were not confounded by depressive disorders. The link between hsCRP and agoraphobia but not panic disorder may be attributable to the trait-like manifestations of agoraphobia versus the episodic fluctuations of panic attacks.
To our knowledge, this study is the first to examine the association between inflammatory markers with the full range of anxiety disorder subtypes. Our findings do not confirm those of a recent cross-sectional population-based study that showed an association between GAD and increased CRP levels in adolescents (Khandaker et al., 2016) . However, the latter study did not adjust for the potentially confounding influences of psychotropic or inflammatory medications. Indeed, a prospective study of children found that the association between GAD and elevated CRP levels was mediated by health-related behaviors, such as BMI and medication (Copeland et al., 2012) . Moreover, consistent with our investigations, they found no association between CRP levels and subsequent GAD (Copeland et al., 2012) . This finding implies that inflammation may be a consequence of anxiety or its correlates, rather than the opposite. Our findings are also inconsistent with the TA B L E 3 Adjusted associations between current and remitted anxiety disorders at baseline and inflammatory markers at follow-up only other study of a population-based sample of older adults that found that CRP was associated with increased psychosocial distress, including anxiety (Das, 2016) . Therefore, future studies are needed to confirm our findings and to explore the potential mechanisms for this association.
Our finding of a lower increase of IL-6 levels over the follow-up period in participants with PTSD at baseline is not consistent with results from several previous cross-sectional studies that showed either increased (Baker et al., 2001; von Kanel et al., 2010) or similar (Miller, Sutherland, Hutchison, & Alexander, 2001; Vidovic et al., 2011 ) levels of IL-6 in patients with PTSD compared to non-PTSD controls. Nevertheless, one previous study also revealed lower IL-6 levels in military veterans with lifetime history of PTSD than in their counterparts without PTSD, after adjustment for sociodemographic factors, health behaviors, traditional cardiovascular risk factors, and medications (Plantinga et al., 2013) . As IL-6 may also act as an anti-inflammatory cytokine through stimulation of the HPA axis, the authors of the study argued that low IL-6 levels could reflect long-term suppression of the anti-inflammatory IL-6 response due to a hypersensitive HPA axis (Plantinga et al., 2013) . In support of such reasoning, we found that current but not remitted PTSD was associated with lower IL-6 levels during the follow-up period compared to non-PTSD controls.
Current, but not remitted, anxiety disorders in our sample were associated with a steeper increase of hsCRP levels over the follow-up period after adjustment for multiple covariates, while only remitted agoraphobia was associated with a steeper increase of TNF-levels over the follow-up period. In cross-sectional analyses, remitted agoraphobia at baseline was not associated with hsCRP levels at baseline, and the same for cross-sectional analyses at follow-up. Further analyses among the remitted agoraphobia group at baseline (n = 34)
showed that these participants had only one episode in their lifetime and the average time in remission was around 14.5 years (S.D. 9.8 years). For hsCRP, but not necessarily for TNF-, these findings suggest that once anxiety has waned, inflammation may also decrease.
Therefore, with respect to anxiety disorders, inflammation seems to be a "scar" which may be persistent for a certain duration of time even after remission. However, after sufficient time, this "scar" may "heal".
Subsequently, future studies should investigate consequences of having had high inflammatory levels and the amount of agoraphobia remission time needed in order to "heal" and not to be anymore at increased risk of consequent cardiovascular diseases. Consequently, the anxiety status should be taken into consideration for the prevention and treatment of chronic inflammation. However, repeated assessments over time of different inflammatory markers would be needed to substantiate such a temporal relationship. Interestingly, in our previous crosssectional analysis, anxiety disorders were associated with lower levels of hsCRP (Glaus et al., 2014) . At the time, we suggested that this association may have been attributable to the low BMI of subjects with anxiety disorders (Glaus et al., 2014) . This may be less the case in this TA B L E 4 Associations between inflammatory markers at baseline and anxiety disorders at follow-up (n = 2,573) Note: IL-6 = Interleukin-6; TNF-= Tumor Necrosis Factor-; hsCRP = high sensitivity C-Reactive Protein; GAD = Generalized Anxiety Disorder; OR = odds ratio; CI = confidence interval.
Levels of Inflammatory
Marker at
P-value OR (95% CI)
P-value
Model 1: adjusted for the corresponding anxiety disorder at baseline. Model 2: adjusted for the corresponding anxiety disorder at baseline, length of follow-up, sociodemographic variables (gender, age, socioeconomic status, ethnicity, and marital status), medications (antidepressants, mood stabilizers, antipsychotics, anxiolytics, aspirin, statin, nonsteroidal anti-inflammatories), health-related behaviors (former smoker, current smoker and physical inactivity), and physical cardiovascular risk factors (body mass index, diabetes, dyslipidemia, and hypertension) at baseline. P-values are in italic.
longitudinal study since we controlled for BMI. However, further longitudinal analysis of the associations between anxiety disorders and BMI and other measures of adiposity are needed to better elucidate these contradictory results.
The finding of a prospective association of anxiety disorders with CRP in our study may provide one explanation for the link between anxiety and an increased risk of future coronary heart disease (CHD) and CVD mortality in the general population reported in a recent metaanalysis of more than two millions of participants (Emdin et al., 2016) .
The acute phase reactant CRP is arguably the most established circulating inflammatory biomarker of increased CVD (Vlachopoulos et al., 2015) , which has been shown to add prognostic information on future CVD risk above and beyond the Framingham CHD risk score (Pearson et al., 2003) . showing a two-fold higher relative risk of CHD than the low risk group (Pearson et al., 2003) . Therefore, a 78% increase in the CRP median level in individuals with agoraphobia compared with the average CRP level in our cohort may seem a clinically meaningful difference in the relative risk of CHD.
One candidate mechanism that may facilitate inflammation and elevated hsCRP in anxiety disorders is autonomic nervous system dysfunction as reflected in reduced heart rate variability (Chalmers, Quintana, Abbott, & Kemp, 2014 ) that is associated with heightened inflammation (Haensel, Mills, Nelesen, Ziegler, & Dimsdale, 2008 ). Although we did not investigate potential mechanisms, such as autonomic nervous system and HPA axis dysfunction, that might play a specific role in increased inflammation in agoraphobia as opposed to the other anxiety disorders, as noted above, these systems may be more chronically dysregulated in more stable conditions such as agoraphobia. As a consequence, sympathetic arousal and stress hormone production could be more sustained in agoraphobia through kindling of greater chronic low-grade inflammation (Elenkov, 2008) . However, this remains speculative as, to our knowledge, systematic investigations on autonomic, neuroendocrine, and immune function in patients with agoraphobia (without panic disorder) in comparison with other anxiety disorders, including PTSD and OCD, have not previously been performed.
Our results should be interpreted in the context of several limitations. First, there was an interval of almost 1 year between the physical and the psychiatric evaluations. Although the timing of anxiety episodes was elicited in our diagnostic interviews, we cannot exclude misclassification regarding the "current" status of disorders at the time of the physical evaluation. Second, similar to most prior studies, inflammatory markers were only assessed once at baseline and again at follow-up, and thus did not reflect the dynamic changes of inflammatory markers over time. However, the majority of previous studies also collected only a single measure per assessment. Third, lowgrade inflammation was measured by hsCRP and cytokine levels, but other potential biomarkers of inflammation, such as anti-inflammatory cytokines and white blood cells were not included. Despite these limitations, this is one of the largest prospective studies of a community sample, with the hitherto longest follow-up period. It is the first study to investigate the full range of anxiety disorder subtypes, measuring both inflammatory markers and anxiety disorders at both times which design permitted us to disentangle some of the bidirectional associations. Moreover, this study is the first that distinguished anxiety as a state versus a trait marker. To our knowledge, no previous studies looked at both current and remitted anxiety disorders in association with subsequent inflammation.
CONCLUSION
The results of this study suggest a direct association between current anxiety disorders at baseline and chronic low-grade inflammation at follow-up. In particular, current agoraphobia was prospectively associated with a steeper increase of hsCRP levels and PTSD was associated with a lower increase of IL-6 levels over the follow-up period. Because anxiety disorders were prospectively associated with changes in these inflammatory markers that were not associated in remitted cases, these findings suggest that inflammation may be a consequence rather than risk factor for anxiety disorders. Further prospective studies with repeated assessments of inflammatory markers earlier in development are required to confirm potential mechanisms for the potential causal link between anxiety disorders and inflammation.
